Bidiphar (DBD) Sets 20% Cash Dividend, Record Date Aug 28
This Aveluro analysis covers DBD on HOSE in the Health Care sector. The classified event type is dividend announcement, with positive sentiment and a deterministic market-impact score of 5.6/10. Aveluro classifies this story as a positive catalyst in the stock's news coverage. Source coverage came from CafeF - Thị trường chứng khoán, classified as a primary/top-tier source.
Key Facts
Caveat: Not investment advice. · How Aveluro computed this: Aveluro combines extracted event facts, source credibility, ticker context, and market data. Scores are deterministic research signals, not recommendations.
Overview
Bidiphar (DBD), listed on HOSE, has announced a 20% cash dividend for 2025, with the record date set for August 28, 2026, and payment on October 1, 2026. The company reported a slight decline in Q2 2026 net profit, while total assets grew 8.2% year-to-date. This dividend announcement comes amid rising inventory and debt levels, which may warrant investor attention.
Key Facts
- Cash dividend rate: 20% (VND 2,000 per share) for fiscal year 2025.
- Record date: August 28, 2026; payment date: October 1, 2026.
- Total payout: approximately VND 189 billion, based on 94.5 million outstanding shares.
- Q2 2026 net profit: VND 89.2 billion, down slightly year-on-year.
- H1 2026 revenue: VND 919.8 billion, up VND 4 billion; net profit: VND 169.5 billion, down VND 1.8 billion.
- Total assets as of June 30, 2026: VND 2,809.9 billion, up 8.2% from start of year.
- Inventory increased 45% to VND 530.8 billion; total liabilities rose 24.7% to VND 1,072.9 billion.
What Happened
Bidiphar (Dược - Trang Thiết bị Y tế Bình Định) announced via a board resolution that it will pay a 20% cash dividend for 2025. Shareholders on record as of August 28, 2026, will receive VND 2,000 per share, with payment scheduled for October 1, 2026. The company will disburse nearly VND 189 billion for this dividend.
In its Q2 2026 financial report, Bidiphar recorded net revenue of VND 471.7 billion, a slight decline from the same period last year. Gross profit fell 7% to VND 225.4 billion. However, financial income surged 106% to VND 10.3 billion, and profit from associates rose from VND 3.6 billion to VND 8.7 billion. Net profit for the quarter was VND 89.2 billion, down marginally year-on-year.
Market Context
DBD closed at VND 49,250 on August 16, 2026, on HOSE. The stock trades in the pharmaceutical sector, which has been relatively stable amid broader market fluctuations. The dividend yield at the current price is approximately 4.1%, which is attractive for income-focused investors. However, the company’s balance sheet shows rising inventory (up 45%) and liabilities (up 24.7%), which could pressure future margins if not managed.
Strategic Significance
Bidiphar’s consistent dividend payout reflects its stable cash flow generation, even as net profit slightly declined. The increase in inventory and long-term assets under construction suggests ongoing investment in capacity or product development, which may support long-term growth. However, the rise in debt and payables indicates higher financial leverage, which investors should monitor. The dividend announcement reinforces management’s commitment to shareholder returns, but the sustainability of such payouts depends on the company’s ability to convert inventory into sales and manage its debt levels.
What to Watch
- Q3 2026 earnings release, expected in late October 2026, to see if revenue growth resumes.
- Inventory turnover ratio in the coming quarters; a continued rise could signal demand weakness.
- Debt levels and interest coverage; watch for any refinancing or new borrowings.
- Progress on long-term assets under construction (VND 621.9 billion) and their impact on future capacity.
- Any regulatory changes in Vietnam’s pharmaceutical sector that could affect pricing or competition.